Screener
Regenxbio RGNX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Deferred revenue | 9,882 | 10,452 |
| Operating lease liabilities | 7,355 | 8,286 |
| Royalty monetization liabilities | 26,765 | 39,609 |
| Total current liabilities | 82,621 | 118,095 |
| Deferred revenue | 15,404 | 18,943 |
| Operating lease liabilities | 61,596 | 65,215 |
| Royalty monetization liabilities | 154,746 | 147,408 |
| Other liabilities | 486 | 638 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's total current liabilities?
- Regenxbio (RGNX) reported total current liabilities of $82.62M in Q2 2026.
- How has Regenxbio's total current liabilities changed year-over-year?
- Regenxbio's total current liabilities decreased by 30.9% year-over-year, from $119.54M to $82.62M.
- What is the long-term trend for Regenxbio's total current liabilities?
- Over 5 years (2020 to 2025), Regenxbio's total current liabilities has grown at a 7.7% compound annual growth rate (CAGR), from $81.45M to $118.1M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Regenxbio's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude